<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579137</url>
  </required_header>
  <id_info>
    <org_study_id>21123-MASCI</org_study_id>
    <nct_id>NCT00579137</nct_id>
    <nct_alias>NCT00609258</nct_alias>
  </id_info>
  <brief_title>Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders</brief_title>
  <acronym>MASCI</acronym>
  <official_title>CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to discover whether children with severe combined immunodeficiency disease&#xD;
      (SCID) or other primary immunodeficiency disorder (PID) for which no satisfactory treatment&#xD;
      other than stem cell transplantation (SCT) exists can be safely and effectively transplanted&#xD;
      from HLA mismatched (up to one haplotype) related donors or unrelated matched or mismatched&#xD;
      (up to one antigen) donors, when leukocytolytic monoclonal antibodies (MAb) and Fludarabine&#xD;
      are the sole conditioning agents. Three monoclonal antibodies will be used in combination.&#xD;
      Two of them are rat IgG1 (immunoglobulin G1) antibodies directed against two contiguous&#xD;
      epitopes on the CD45 (common leucocyte) antigen. They have been safely administered as part&#xD;
      of the conditioning regimen for 12 patients receiving allografts (HLA matched and mismatched)&#xD;
      at this center. They produce a transient depletion of &gt;90% circulating leucocytes. The third&#xD;
      MAb is Campath 1H, a humanized rat anti-CD52 MAb. Campath 1H, Alemtuzumab, has been licensed&#xD;
      to treat B-cell chronic lymphocytic leukemia (B-CLL) and more recently has been safely given&#xD;
      at this and other centers as part of a sub-ablative conditioning regimen to patients with&#xD;
      malignant disease. Because these MAb produce both profound immunosuppression and significant,&#xD;
      though transient, myelodestruction we believe they may be useful as the sole conditioning&#xD;
      regimen in patients with SCID, in whom the use of conventional chemotherapeutic agents for&#xD;
      conditioning may produce or aggravate unacceptable and even lethal short term toxicity. We&#xD;
      anticipate MAb mediated subablative conditioning will permit engraftment in a high percentage&#xD;
      of these patients with little or no immediate or long term toxicity. Campath IH persists in&#xD;
      vivo for several days after administration and so will be present over the transplant period&#xD;
      to deplete donor T cells as partial GvHD prophylaxis. Additional Graft versus Host Disease&#xD;
      (GvHD) prophylaxis may be provided by administration of FK506.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Donor Stem Cell Processing for Mismatched Donors: Harvested peripheral blood stem cells will&#xD;
      be enriched for CD34 cells using the CliniMACS CD34 Reagent system, according to Center for&#xD;
      Cell and Gene Therapy (CAGT) SOPs.&#xD;
&#xD;
      Stem Cell Transplant Conditioning&#xD;
&#xD;
      Campath-1H will be given as 3 daily intravenous infusions and will be followed by Anti-CD45&#xD;
      which will be given as four daily intravenous infusions that will be completed two days prior&#xD;
      to stem cell infusion. Diphenydramine will be administered i.v. q4h during the period of the&#xD;
      course of the Campath and Anti-CD45 infusions.&#xD;
&#xD;
      Day&#xD;
&#xD;
      8 Campath 1H as per CAGT SOP Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
&#xD;
      7 Campath 1H as per CAGT SOP Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
&#xD;
      6 Campath 1H as per CAGT SOP Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
&#xD;
      5 YTH 24/54 400ug/kg over 6 hr Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
&#xD;
      4 YTH 24/54 400ug/kg over 6 hr Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
&#xD;
      3 YTH 24/54 400ug/kg over 6 hr&#xD;
&#xD;
      2 YTH 24/54 400ug/kg over 6 hr&#xD;
&#xD;
      1 rest&#xD;
&#xD;
      0 Stem Cell Infusion&#xD;
&#xD;
      Campath 1H Infusion- Campath dose is weight based: for patients less than 15 killograms (kg)&#xD;
      administer Campath 3 mg; for patients &gt;15 kg to 30 kg administer Campath 5 mg; for patients &gt;&#xD;
      30 kg administer Campath 10 mg. Campath will be dosed and administered as per CAGT SOP.&#xD;
&#xD;
      Anti-CD45- Infusion Anti-CD45 infusion will be administered according to CAGT SOPs. 3 ml of&#xD;
      heparinized blood will be drawn 48 hr post Anti-CD45 to evaluate for free Anti-CD45 levels in&#xD;
      the plasma. This estimation will be used to determine whether treatment with irradiated&#xD;
      leukocytes is required before the bone marrow is infused.&#xD;
&#xD;
      GVHD Prophylaxis- GVHD prophylaxis will be achieved through positive selection for CD34&#xD;
      resulting in &gt; 3 log T cell depletion. Previous reports have indicated that there is a low&#xD;
      frequency of severe (Grade II/IV) GVHD after haploidentical transplants if recipients receive&#xD;
      stem cell populations containing &lt;5 x 10 CD3 positive T cells. We hope to achieve such levels&#xD;
      with our CD34 enrichment protocol. However, pharmacologic prophylaxis will be added if the&#xD;
      CD34 selected product contains more than 5 x 10 CD3+ve T cells/kg recipient weight. In&#xD;
      addition, Campath 1H persists in the recipient circulation through the immediate transplant&#xD;
      period and will contribute anti-GVHD activity, in vivo. Patients who develop acute or chronic&#xD;
      GVHD will be managed according to CAGT SOPs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Donor Engraftment</measure>
    <time_frame>100 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Alive at 1 Year</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III or IV Toxicity</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III to IV Acute GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Severe Combined Immunodeficiency Disease</condition>
  <condition>Severe Primary Immunodeficiency Disorder</condition>
  <condition>Undefined T Cell Deficiency Disorder</condition>
  <condition>Wiskott-Aldrick Syndrome</condition>
  <arm_group>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath -1H</intervention_name>
    <description>Given intravenous on Days -8,-7, and -6&#xD;
Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients &gt;15 kg to 30 kg the dose 5 mg; for patients &gt; 30 kg the dose is 10 mg</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given intravenous on Days -8,-7,-6,-5, and -4&#xD;
Dose is 30 mg/m2</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD45</intervention_name>
    <description>Given intravenous over 6 hours on Days -5,-4,-3, and -2&#xD;
Dose is 400 microgram/kg</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell infusion</intervention_name>
    <description>stem cells are infused on day 0</description>
    <arm_group_label>Participants With SCID or Primary Immunodeficiency Disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with a diagnosis of: Severe combined immunodeficiency disease&#xD;
&#xD;
        This includes patients whose SCID is characterized by gene specific mutations as well as&#xD;
        patients with clinically severe combined immunodeficiency without a defined genetic cause&#xD;
        in which the diagnosis will be determined by a combination of clinical course with&#xD;
        lymphocyte quantification and function assays.&#xD;
&#xD;
        OR&#xD;
&#xD;
        Severe primary immunodeficiency disorder, including undefined T cell deficiency disorder,&#xD;
        Wiskott-Aldrich syndrome, and other severe immunodeficiencies for which satisfactory&#xD;
        conventional therapy does not exist.&#xD;
&#xD;
          -  Availability of an HLA mismatched (up to one haplotype) family member or an HLA&#xD;
             matched or mismatched (up to one antigen) unrelated donor.&#xD;
&#xD;
          -  Creatinine &lt; 2.5 x normal for age.&#xD;
&#xD;
          -  Life expectancy greater than 6 weeks&#xD;
&#xD;
          -  Lansky/Karnofsky greater than or equal to 70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an HLA matched related donor&#xD;
&#xD;
          -  Patients with symptomatic cardiac disease, or evidence of significant cardiac disease&#xD;
             by echocardiogram (i.e., shortening fraction less than 25%)&#xD;
&#xD;
          -  Patients with known allergy to rat serum products&#xD;
&#xD;
          -  Patients with a severe infection that on evaluation by the Principal Investigator&#xD;
             precludes ablative chemotherapy or successful transplantation&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Krance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm Brenner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>March 30, 2013</results_first_submitted>
  <results_first_submitted_qc>June 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Krance</investigator_full_name>
    <investigator_title>Professor Pediatrics Hematology Oncology Center for Cell and Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Severe Combined Immunodeficiency Disease</keyword>
  <keyword>Severe Primary Immunodeficiency Disorder</keyword>
  <keyword>Undefined T cell Deficiency Disorder</keyword>
  <keyword>Wiskott-Aldrick Syndrome</keyword>
  <keyword>Allogeneic stem cell transplant</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>monoclonal antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants With SCID or Primary Immunodeficiency Disorder</title>
          <description>Participants received an allogeneic stem cell transplant with the following conditioning:&#xD;
Day 8 Campath 1H as per CAGT SOP, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
D7 Campath 1H as per CAGT SOP, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
D6 Campath 1H as per CAGT SOP, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
D5 Anti-CD45 MAb 400ug/kg over 6 hr, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
D4 Anti-CD45 MAb 400ug/kg over 6 hr, Fludarabine 10 kg or less: 1 mg/kg; &gt; 10 kg: 30 mg/m2&#xD;
D3 Anti-CD45 MAb 400ug/kg over 6 hr&#xD;
D2 Anti-CD45 MAb 400ug/kg over 6 hr&#xD;
D1 rest&#xD;
D0 Stem Cell Infusion&#xD;
Campath dose is weight based: for patients less than 15 kg administer Campath 3 mg; for patients &gt;15 kg to 30 kg administer Campath 5 mg; for patients &gt; 30 kg administer Campath 10 mg. Campath will be dosed and administered as per CAGT SOP.&#xD;
Anti-CD45 infusion will be administered according to CAGT SOPs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Group</title>
          <description>only one group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=1 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Donor Engraftment</title>
        <time_frame>100 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Donor Engraftment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Alive at 1 Year</title>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Alive at 1 Year</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III or IV Toxicity</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III or IV Toxicity</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III to IV Acute GVHD</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III to IV Acute GVHD</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Group</title>
          <description>only one group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other: Liver GvHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other: Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other: Livedo reticularis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Krance, MD</name_or_title>
      <organization>Baylor</organization>
      <phone>832-824-4661</phone>
      <email>rkrance@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

